GlassScriptPhysician profile
David M Lobas
NPI 1619039534
$158,042.79
in general payments reported to CMS, 2019-2025
60 companies · $5,058 in 2025
The $5,058 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $40K · 2021: $37K · 2022: $13K · 2023: $21K · 2024: $8,212 · 2025: $5,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $8,596 · Travel and Lodging: $177 · Education: $43.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,499.00 |
| Food and Beverage | $8,596.29 |
| Travel and Lodging | $177.17 |
| Education | $43.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $35,411.46 | 2019-2023 | Austedo Xr, Austedo |
| Abbvie INC. | $32,007.86 | 2021-2025 | |
| Genzyme Corporation | $20,707.80 | 2019-2025 | |
| Allergan, INC. | $16,675.28 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $12,643.28 | 2019-2021 | |
| Ucb, INC. | $12,104.62 | 2019-2025 | Nayzilam, Briviact |
| Mdd US Operations, LLC | $4,911.33 | 2019-2022 | |
| Livanova USA, INC. | $4,858.98 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Sk Life Science, INC. | $2,532.75 | 2020-2024 | Xcopri |
| Emd Serono, INC. | $1,471.97 | 2019-2025 | Mavenclad, Mavenclad |
| Lundbeck LLC | $1,267.26 | 2019-2025 | Vyepti |
| Lilly USA, LLC | $1,136.12 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Biogen, INC. | $959.44 | 2020-2025 | Vumerity, Tysabri |
| Novartis Pharmaceuticals Corporation | $819.28 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $784.01 | 2019-2025 | Ingrezza, Ongentys |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lobas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.